Ariad Pharmaceuticals ( ARIA) is a biopharmaceutical company focused on the discovery and development of drugs to provide therapeutic intervention in treating human diseases at the cellular level. This stock is trading up 2.8% at $13.59 in recent trading after hitting a 52-week high of $13.66 earlier in the day. Today's Range: $13.20-$13.66 52-week Range: $5.06-$13.50 Volume: 1.8 million Three-Month Average Volume: 3.15 million Ariad Pharmaceuticals has a market cap of $1.80 billion and an enterprise value of $1.68 billion. The stock trades at a price-to-sales of 68.13 and a price-to-book of 65.40. Its estimated growth rate for this year is 134.5%, and for next year it's pegged at 19.4%. The current short interest as a percentage of the float for Ariad Pharmaceuticals stands at 12.8%. From a technical standpoint, ARIA recently triggered a breakout trade when the stock took out some past overhead resistance at $12.50 with solid volume. The stock is now triggering another big breakout trade, with shares moving above some major overhead resistance from July at $13.50. Traders should now look for a sustained high-volume move and close above $13.50 to signal that ARIA wants to trend significantly higher. Look for volume that's near or above its average action of 3.15 million shares. Ariad shows up on a list of 10 Biotech Stocks Loved and Hated by Wall Street's Top Investment Pros for the most recently reported quarter.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.